Communique of GTTAC Meeting of 4 August 2015
This Communiqué covers matters considered at the 48th meeting of the Gene Technology Technical Advisory Committee (4 August 2015).
AstraZeneca Pty Ltd has applied for a licence for the commercial supply of two types of genetically modified (GM) influenza vaccines: a seasonal flu vaccine to target currently circulating flu viruses; and one to target a pandemic flu strain, should one arise. GM vaccines based on the same attenuated strains as the GMOs are currently approved in United States of America (USA), Canada and the European Union. If approved in Australia the GMOs would be imported from overseas and distributed to healthcare facilities where the vaccines would be administered as a nasal spray by qualified health professionals to consenting patients.